{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:00:55Z","timestamp":1785528055259,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP22K10547"],"award-info":[{"award-number":["JP22K10547"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP22K17408"],"award-info":[{"award-number":["JP22K17408"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Clinical Infectious Diseases, Nagoya City University Graduate School of Medical Sciences"},{"name":"Outstanding Research Group Support Program in Nagoya City University","award":["2530003"],"award-info":[{"award-number":["2530003"]}]},{"name":"NCGM Intramural Research Fund","award":["22A1007"],"award-info":[{"award-number":["22A1007"]}]},{"name":"Shionogi & Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54591-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:34:55Z","timestamp":1779514495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Carbapenem-resistant Gram-negative bacilli infections in Japanese patients with cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Naoya","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"54591_CR1","unstructured":"World Health Organization. WHO bacterial priority pathogens list. : Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. (2024). https:\/\/www.who.int\/publications\/i\/item\/9789240093461 (2024)."},{"key":"54591_CR2","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann, P. & Poirel, L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin. Infect. Dis. 69, S521\u2013S528. https:\/\/doi.org\/10.1093\/cid\/ciz824 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"54591_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","volume":"75","author":"D van Duin","year":"2013","unstructured":"van Duin, D., Kaye, K. S., Neuner, E. A. & Bonomo, R. A. Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes. Diagn. Microbiol. Infect. Dis. 75, 115\u2013120. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.11.009 (2013).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"54591_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx176","author":"B Cai","year":"2017","unstructured":"Cai, B. et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofx176 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"54591_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263095","volume":"17","author":"N Itoh","year":"2022","unstructured":"Itoh, N. et al. Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: An interrupted time-series analysis. PLoS One. 17, e0263095. https:\/\/doi.org\/10.1371\/journal.pone.0263095 (2022).","journal-title":"PLoS One."},{"key":"54591_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s10096-020-03839-2","volume":"39","author":"MM Tawfick","year":"2020","unstructured":"Tawfick, M. M., Alshareef, W. A., Bendary, H. A., Elmahalawy, H. & Abdulall, A. K. The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients. Eur. J. Clin. Microbiol. Infect. Dis. 39, 1251\u20131259. https:\/\/doi.org\/10.1007\/s10096-020-03839-2 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"54591_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21505594.2016.1213472","volume":"8","author":"SM Pouch","year":"2017","unstructured":"Pouch, S. M. & Satlin, M. J. Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence 8, 391\u2013402. https:\/\/doi.org\/10.1080\/21505594.2016.1213472 (2017).","journal-title":"Virulence"},{"key":"54591_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cncr.21115","volume":"104","author":"N Ohmagari","year":"2005","unstructured":"Ohmagari, N. et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104, 205\u2013212. https:\/\/doi.org\/10.1002\/cncr.21115 (2005).","journal-title":"Cancer"},{"key":"54591_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","volume":"73","author":"MJ Satlin","year":"2016","unstructured":"Satlin, M. J. et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J. Infect. 73, 336\u2013345. https:\/\/doi.org\/10.1016\/j.jinf.2016.07.002 (2016).","journal-title":"J. Infect."},{"key":"54591_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma, P. D. et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 72, 1109\u20131116. https:\/\/doi.org\/10.1093\/cid\/ciaa1478 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"54591_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jgar.2022.04.004","volume":"29","author":"K Oka","year":"2022","unstructured":"Oka, K. et al. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J. Glob. Antimicrob. Resist. 29, 247\u2013252. https:\/\/doi.org\/10.1016\/j.jgar.2022.04.004 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"54591_CR12","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute. (2021)."},{"key":"54591_CR13","unstructured":"CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. CLSI Guideline m45. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute. (2016)."},{"key":"54591_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae168","volume":"6","author":"R Hase","year":"2024","unstructured":"Hase, R. et al. Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan. J. Antimicrob. Chemother. 6, dkae168. https:\/\/doi.org\/10.1093\/jac\/dkae168 (2024).","journal-title":"J. Antimicrob. Chemother."},{"issue":"2022","key":"54591_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014217","volume":"2","author":"K Crider","year":"2022","unstructured":"Crider, K. et al. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Cochrane Database Syst. Rev. 2(2022), CD014217. https:\/\/doi.org\/10.1002\/14651858.CD014217 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"18","key":"54591_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","volume":"97","author":"PC Austin","year":"2021","unstructured":"Austin, P. C., Yu, A. Y. X., Vyas, M. V. & Kapral, M. K. Applying propensity score methods in clinical research in neurology. Neurology 97(18), 856\u2013863. https:\/\/doi.org\/10.1212\/WNL.0000000000012777 (2021).","journal-title":"Neurology"},{"issue":"1","key":"54591_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li, F., Thomas, L. E. & Li, F. Addressing extreme propensity scores via the overlap weights. Am. J. Epidemiol. 188(1), 250\u2013257. https:\/\/doi.org\/10.1093\/aje\/kwy201 (2019).","journal-title":"Am. J. Epidemiol."},{"key":"54591_CR18","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1093\/jac\/dkv218","volume":"70","author":"N Andria","year":"2015","unstructured":"Andria, N. et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: A retrospective cohort study. J. Antimicrob. Chemother. 70, 3146\u20133153. https:\/\/doi.org\/10.1093\/jac\/dkv218 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"54591_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ijantimicag.2006.11.006","volume":"29","author":"GL Daikos","year":"2007","unstructured":"Daikos, G. L. et al. VIM-1-producing Klebsiella pneumoniae bloodstream infections: Analysis of 28 cases. Int. J. Antimicrob. Agents. 29, 471\u2013473. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.11.006 (2007).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"54591_CR20","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.00782-08","volume":"53","author":"GL Daikos","year":"2009","unstructured":"Daikos, G. L. et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53, 1868\u20131873. https:\/\/doi.org\/10.1128\/AAC.00782-08 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54591_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jmii.2010.06.001","volume":"44","author":"HJ Chang","year":"2011","unstructured":"Chang, H. J. et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case-control study. J. Microbiol. Immunol. Infect. 44, 125\u2013130. https:\/\/doi.org\/10.1016\/j.jmii.2010.06.001 (2011).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"54591_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1086\/657135","volume":"31","author":"E Mouloudi","year":"2010","unstructured":"Mouloudi, E. et al. Bloodstream infections caused by metallo-\u03b2-lactamase\/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: Risk factors for infection and impact of type of resistance on outcomes. Infect. Control. Hosp. Epidemiol. 31, 1250\u20131256. https:\/\/doi.org\/10.1086\/657135 (2010).","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"54591_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1086\/592412","volume":"29","author":"G Patel","year":"2008","unstructured":"Patel, G., Huprikar, S., Factor, S. H., Jenkins, S. G. & Calfee, D. P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29, 1099\u20131106. https:\/\/doi.org\/10.1086\/592412 (2008).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"54591_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","volume":"18","author":"D Ben-David","year":"2012","unstructured":"Ben-David, D. et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin. Microbiol. Infect. 18, 54\u201360. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03478.x (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"54591_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1128\/AAC.01020-07","volume":"52","author":"MJ Schwaber","year":"2008","unstructured":"Schwaber, M. J. et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother. 52, 1028\u20131033. https:\/\/doi.org\/10.1128\/AAC.01020-07 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54591_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","volume":"161","author":"TR Zembower","year":"2014","unstructured":"Zembower, T. R. Epidemiology of infections in cancer patients. Cancer Treat. Res. 161, 43\u201389. https:\/\/doi.org\/10.1007\/978-3-319-04220-6_2 (2014).","journal-title":"Cancer Treat. Res."},{"key":"54591_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01422","volume":"11","author":"R Lalaoui","year":"2020","unstructured":"Lalaoui, R., Javelle, E., Bakour, S., Ubeda, C. & Rolain, J. M. Infections due to carbapenem-resistant bacteria in patients with hematologic malignancies. Front. Microbiol. 11, 1422. https:\/\/doi.org\/10.3389\/fmicb.2020.01422 (2020).","journal-title":"Front. Microbiol."},{"key":"54591_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2015.09.015","volume":"22","author":"A Xu","year":"2016","unstructured":"Xu, A. et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin. Microbiol. Infect. 22, S1\u2013S8. https:\/\/doi.org\/10.1016\/j.cmi.2015.09.015 (2016).","journal-title":"Clin. Microbiol. Infect."},{"key":"54591_CR29","unstructured":"Japan nosocomial infections surveillance. Annual open report. (2021). https:\/\/janis.mhlw.go.jp\/report\/open_report\/2021\/3\/1\/ken_Open_Report_202100_Outpatient.pdf"},{"key":"54591_CR30","doi-asserted-by":"publisher","first-page":"e01243","DOI":"10.1128\/AAC.01243-16","volume":"61","author":"DJ Buehrle","year":"2016","unstructured":"Buehrle, D. J. et al. Carbapenem-resistant pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob. Agents Chemother. 61, e01243\u2013e01316. https:\/\/doi.org\/10.1128\/AAC.01243-16 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54591_CR31","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3201\/eid2007.121004","volume":"20","author":"ME Falagas","year":"2014","unstructured":"Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E. & Vardakas, K. Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg. Infect. Dis. 20, 1170\u20131175. https:\/\/doi.org\/10.3201\/eid2007.121004 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"54591_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/mdr.2009.0031","volume":"16","author":"M Castanheira","year":"2010","unstructured":"Castanheira, M., Sader, H. S. & Jones, R. N. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug Resist. 16, 61\u201365. https:\/\/doi.org\/10.1089\/mdr.2009.0031 (2010).","journal-title":"Microb. Drug Resist."},{"key":"54591_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","volume":"10","author":"KK Kumarasamy","year":"2010","unstructured":"Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597\u2013602. https:\/\/doi.org\/10.1016\/S1473-3099(10)70143-2 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"54591_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/cid\/ciw741","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma, P. D. et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin. Infect. Dis. 64, 257\u2013264. https:\/\/doi.org\/10.1093\/cid\/ciw741 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"54591_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1469-0691.12697","volume":"20","author":"LS Tzouvelekis","year":"2014","unstructured":"Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M. & Daikos, G. L. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 20, 862\u2013872. https:\/\/doi.org\/10.1111\/1469-0691.12697 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"54591_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez, B. et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. Lancet Infect. Dis. 17, 726\u2013734. https:\/\/doi.org\/10.1016\/S1473-3099(17)30228-1 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"54591_CR37","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","volume":"215","author":"LK Logan","year":"2017","unstructured":"Logan, L. K. & Weinstein, R. A. The epidemiology of carbapenem-resistant Enterobacteriaceae: The impact and evolution of a global menace. J. Infect. Dis. 215, S28\u2013S36. https:\/\/doi.org\/10.1093\/infdis\/jiw282 (2017).","journal-title":"J. Infect. Dis."},{"key":"54591_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jiac.2018.11.012","volume":"25","author":"H Yamakawa","year":"2019","unstructured":"Yamakawa, H. et al. Molecular and epidemiological analysis of IMP-1 metallo-\u03b2-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. J. Infect. Chemother. 25, 240\u2013246. https:\/\/doi.org\/10.1016\/j.jiac.2018.11.012 (2019).","journal-title":"J. Infect. Chemother."},{"key":"54591_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhin.2017.07.015","volume":"97","author":"N Yamamoto","year":"2017","unstructured":"Yamamoto, N. et al. Prevalence of, and risk factors for, carriage of carbapenem-resistant Enterobacteriaceae among hospitalized patients in Japan. J. Hosp. Infect. 97, 212\u2013217. https:\/\/doi.org\/10.1016\/j.jhin.2017.07.015 (2017).","journal-title":"J. Hosp. Infect."},{"key":"54591_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jiac.2016.12.013","volume":"23","author":"Y Ohno","year":"2017","unstructured":"Ohno, Y. et al. Molecular epidemiology of carbapenemase-producing Enterobacteriaceae in a primary care hospital in Japan, 2010\u20132013. J. Infect. Chemother. 23, 224\u2013229. https:\/\/doi.org\/10.1016\/j.jiac.2016.12.013 (2017).","journal-title":"J. Infect. Chemother."},{"key":"54591_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281518","volume":"18","author":"N Itoh","year":"2023","unstructured":"Itoh, N. et al. Reduction strategies for inpatient oral third-generation cephalosporins at a cancer center: An interrupted time-series analysis. PLoS One 18, e0281518. https:\/\/doi.org\/10.1371\/journal.pone.0281518 (2023).","journal-title":"PLoS One"},{"key":"54591_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05380-6","volume":"20","author":"N Itoh","year":"2020","unstructured":"Itoh, N. et al. Infectious disease specialist consultations in a Japanese cancer center: A retrospective review of 776 cases. BMC Health Serv. Res. 20, 500. https:\/\/doi.org\/10.1186\/s12913-020-05380-6 (2020).","journal-title":"BMC Health Serv. Res."},{"key":"54591_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae678","volume":"11","author":"N Itoh","year":"2024","unstructured":"Itoh, N. et al. Efficiency of a Long-term Infectious Diseases Consultation and Antimicrobial Stewardship Program at a Japanese Cancer Center: An interrupted time-series analysis. Open Forum Infect. Dis. 11, ofae678. https:\/\/doi.org\/10.1093\/ofid\/ofae678 (2024).","journal-title":"Open Forum Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54591-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:17Z","timestamp":1785521837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54591-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54591"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54591-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. has received a research grant from Shionogi. Y.D. reports consulting fees from GSK, Meiji Seika Pharma, Shionogi, Gilead, Moderna; and speaker payments from Shionogi and Gilead. T.M. has received speaker payments from MSD, Pfizer, and Gilead. All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the National Center for Global Health and Medicine (NCGM-S-003163) centrally approved this study on November 10, 2023, followed by approval of the study at each participating site, with granting of the opt-out process for informed consent. This study was conducted according to the principles of the Declaration of Helsinki. The requirement for written informed consent was waived due to the observational nature of the study, and an opt-out approach was used.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23572"}}